Hans P. Schmid

Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD.

Essetifin SpA operates as a holding company. The company was founded in 1957 and is headquartered in Rome, Italy.

Entvantage Diagnostics, Inc. develops diagnostic test kits. It includes Collection device and Assay kit products. The company was founded by Joseph Skraba in 2014 and is headquartered in Austin, TX.

Cytori Therapeutics, Inc. develops treatments and devices for cell therapy. The private company is based in San Diego, CA.

Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY.

NovaMed Pharmaceuticals Inc. engages in pharmaceutical preparations. It manufactures and distributes healthcare and pharmaceutical products. The company was founded by Mark Lotter, Min Geng Xiao and Bo Shao on August 1, 2005 and is headquartered in Shanghai, China.

Autism Consortium operates as an online collaboration platform for healthcare professionals. The non-profit company is based in Boston, MA.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.

Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands.

HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001.

Children's Hospital Corp. engages in the provision of pediatric care services. It offers acupuncture, angioplasty, antibiotic allergy testing, audiogram, baclofen pump, biochemical genetic testing, blended diet, bone scan, brain scan, breast augmentation surgery, cardiac catheterization, cardiac MRI in children, chest reconstruction surgery, and CO2 laser treatment. The company was founded by Francis Henry Brown in 1869 and is headquartered in Boston, MA.

Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.

Perkin Elmer Corp. provides solutions for diagnostics, life sciences, food, and applied markets. The private company is based in Norwalk. The American company's accurate and robust instrumentation and sample handling technologies support the work of regulatory bodies and industry scientists in PPCPs analysis. The company's life sciences products include detection and imaging systems, assays and reagents, automation solutions, informatics platforms, and services.

Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA.

Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA.

Life Sciences Group, Inc. operates as an American biotechnology company.

Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts.

Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA.

The Pritzker Organization LLC (TPO) is a private equity subsidiary of PRITZKER FAMILY founded in 2002 by Tom Pritzker. The firm is headquartered in New York.

Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA.

Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.